Finance

Lists
Outlook: 87.5% bullish·0.0% bearish
Go to analysis
TEVA:TLV
Teva Pharmaceutical Industries Limited
12 940,00 ILA
+1,57%
(+200,00) 1D
14 ოქტ, 17:29:42 GMT+3  ·   ILA
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Open
12 730,00 ILA
High
12 940,00 ILA
Low
12 620,00 ILA
Mkt. cap
47,86 მლრდ.
Avg. vol.
1,08 მლნ.
Volume
971,42 ათ.
P/E ratio
70,10
52-wk high
12 940,00 ILA
52-wk low
6 207,00 ILA
EPS
1,85 ILA
Shares outstanding
1,17 მლრდ.
No. of employees
32 ათ.
Open
12 730,00 ILA
High
12 940,00 ILA
Low
12 620,00 ILA
Mkt. cap
47,86 მლრდ.
Avg. vol.
1,08 მლნ.
Volume
971,42 ათ.
P/E ratio
70,10
52-wk high
12 940,00 ILA
52-wk low
6 207,00 ILA
EPS
1,85 ILA
Shares outstanding
1,17 მლრდ.
No. of employees
32 ათ.
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited
CEOრიჩარდ ფრენსის
Employees32 ათ.
Founded13 თებ. 1944
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
4,48 მლრდ.
4,71 მლრდ.
3,98 მლრდ.
4,14 მლრდ.
Cost of goods sold
2,18 მლრდ.
2,06 მლრდ.
2,01 მლრდ.
1,99 მლრდ.
Cost of revenue
2,18 მლრდ.
2,06 მლრდ.
2,01 მლრდ.
1,99 მლრდ.
Research and development expenses
256,00 მლნ.
267,00 მლნ.
222,00 მლნ.
970,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 მლნ.
1,12 მლრდ.
1,00 მლრდ.
1,03 მლრდ.
Operating expense
1,24 მლრდ.
1,37 მლრდ.
1,21 მლრდ.
1,99 მლრდ.
Total operating expenses
3,41 მლრდ.
3,43 მლრდ.
3,22 მლრდ.
3,98 მლრდ.
Operating income
1,07 მლრდ.
1,28 მლრდ.
763,00 მლნ.
167,00 მლნ.
Other non operating income
-27,00 მლნ.
-
-13,00 მლნ.
-69,00 მლნ.
EBT including unusual items
648,00 მლნ.
90,00 მლნ.
436,00 მლნ.
-455,00 მლნ.
EBT excluding unusual items
832,00 მლნ.
1,08 მლრდ.
547,00 მლნ.
-57,00 მლნ.
Income tax expense
214,00 მლნ.
-390,00 მლნ.
67,00 მლნ.
121,00 მლნ.
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 მლნ.
-17,00 მლნ.
-14,00 მლნ.
-18,00 მლნ.
Net income
433,00 მლნ.
480,00 მლნ.
369,00 მლნ.
-576,00 მლნ.
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 მლნ.
-
-
Interest expense
-205,00 მლნ.
-280,00 მლნ.
-191,00 მლნ.
-186,00 მლნ.
Net interest expenses
-205,00 მლნ.
-188,00 მლნ.
-191,00 მლნ.
-186,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 მლრდ.
1,54 მლრდ.
1,00 მლრდ.
408,00 მლნ.
Gain or loss from assets sale
-
-
-8,00 მლნ.
-12,00 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები